Isotopia Molecular Imaging proudly announces the launch of Isoprotrace®, an advanced ⁶⁸Ga PSMA-11 radiolabeling kit designed to enhance diagnostic accuracy and clinical decision-making in prostate cancer.
Isoprotrace® is a ready-to-use, multi-dose kit for the efficient preparation of Gallium-68 PSMA-11, a tracer used in PSMA PET/CT imaging. This innovative solution allows clinicians to visualize prostate-specific membrane antigen (PSMA) expression with exceptional clarity, improving the detection and localization of both primary and recurrent prostate cancer.
The introduction of Isoprotrace® in Malta marks a significant step forward in providing clinicians with reliable, high-quality tools for personalized prostate cancer management. By simplifying the radiolabelling process, the kit ensures consistent results and optimizes workflow efficiency in nuclear medicine departments.
Prostate cancer remains one of the most common malignancies among men worldwide. Early and accurate diagnosis is critical to tailoring treatment strategies and improving patient outcomes. With PSMA PET imaging gaining global recognition for its superior sensitivity and specificity, the availability of Isoprotrace® supports Malta’s healthcare professionals in adopting the latest innovations in molecular imaging.
This launch also reinforces Isotopia’s commitment to advancing access to nuclear medicine technologies across Europe and beyond. The company continues to expand its presence in international markets, driving diagnostic excellence and improving the standard of care for patients worldwide.
About Isotopia Molecular Imaging
Isotopia Molecular Imaging is a global radiopharmaceutical company specializing in the development, manufacturing, and distribution of advanced molecular imaging and therapy products. With a multidisciplinary team and strong international partnerships, Isotopia is dedicated to making molecular imaging simple, precise, and impactful, improving healthcare outcomes across the globe.
